DSDFF-YOLO辅助诊断¹³¹I治疗后全身显像病灶
本研究回顾性分析361例甲状腺癌患者¹³¹I治疗后全身显像,提出DSDFF-YOLO自动检测甲状腺残留、淋巴结转移、肺转移及其他远处转移。在独立测试集上,该模型检测甲状腺残留和淋巴结转移的敏感度分别为85.53%和79.31%,特异度分别为91.11%和93.52%,优于核医学医师。
要点
- 模型对甲状腺残留和淋巴结转移的检测敏感度与特异度均较高,可作为日常阅片参考。
- 该辅助诊断工具可能减少部分患者对SPECT/CT的依赖。
- 自动检测覆盖甲状腺残留、淋巴结转移、肺转移及其他远处转移四类病灶。
核心结论
- DSDFF-YOLO在¹³¹I治疗后全身显像上对甲状腺残留和淋巴结转移具有较高诊断性能。
- 在独立测试集中该模型检测甲状腺残留和淋巴结转移的敏感度与特异度均超过核医学医师。
研究设计与样本
- 回顾性研究,纳入2022年6月至2024年2月361例接受¹³¹I治疗的甲状腺癌患者。
- 验证集62例,平均年龄43.90±13.80岁,女性36例;独立测试集51例,平均年龄44.51±15.51岁,女性22例。
- 提出DSDFF-YOLO模型,设计深度可分离多尺度融合和双控频域自注意力模块,并改进频域动态卷积。
- 与多种现有模型、传统模型及核医学医师进行诊断性能比较。
关键影像表现/征象
- 模型可自动检测¹³¹I治疗后全身显像上的甲状腺残留、淋巴结转移、肺转移及其他远处转移四类病灶。
诊断标准与关键数值
- 验证集DSDFF-YOLO检测甲状腺残留和淋巴结转移的mAP₅₀为0.772,平均精确度为0.801,召回率为0.731。
- 独立测试集检测甲状腺残留的敏感度为85.53%,特异度为91.11%。
- 独立测试集检测淋巴结转移的敏感度为79.31%,特异度为93.52%。
临床应用与阅片要点
- 该模型可作为¹³¹I治疗后全身显像的自动辅助诊断工具,协助医师判断甲状腺残留和淋巴结转移。
- 对肺转移及其他远处转移的检测性能原文未给出与医师比较的敏感度和特异度。
- 临床应用可能减少部分患者对SPECT/CT的检查需求。
局限性
- 回顾性单中心研究,样本量有限。
- 独立测试集中仅报告甲状腺残留和淋巴结转移的敏感度与特异度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Radioiodine-131 (131I) therapy is an important post-thyroidectomy treatment, but lesion diagnosis on post-therapy whole-body scans (RxWBS) is clinically challenging. This study aimed to propose an automated computer-aided diagnostic method for RxWBS that detects four categories of lesions: thyroid remnants, lymph node metastases (mLNs), lung metastases, and other distant metastases.
METHODS: This retrospective study analyzed data from 361 thyroid cancer patients treated with 131I between June 2022 and February 2024. We proposed an automated diagnostic method to assist physicians, in which the DSDFF-YOLO model automatically detects and diagnoses lesions on RxWBS. Moreover, we designed the depthwise-separable multi-scale fusion and the dual-control frequency-domain self-attention modules and additionally improved the frequency-domain dynamic convolution. The DSDFF-YOLO was compared with other state-of-the-art and conventional models, as well as with nuclear medicine physicians, to evaluate its diagnostic performance.
RESULTS: The validation set included 62 patients (mean age 43.90 ± 13.80 years [SD], 36 female patients). The DSDFF-YOLO outperformed others in detecting thyroid remnants and mLNs, achieving a mAP₅₀ of 0.772, mean precision of 0.801, and recall of 0.731. On the independent test set (51 patients, mean age 44.51 ± 15.51 years [SD], 22 female patients), it surpassed nuclear medicine physicians in detecting thyroid remnants and mLNs, with sensitivities of 85.53% and 79.31%, and specificities of 91.11% and 93.52%, respectively.
CONCLUSION: The DSDFF-YOLO enabled effective and accurate automated auxiliary diagnosis based on RxWBS. This method demonstrated excellent diagnostic performance and holds significant potential for clinical application.
KEY POINTS: Question Can Deep Learning effectively assist clinicians in accurately diagnosing whole-body lesions on post-therapy radioiodine whole-body scans, rather than remaining confined to cervical lesions? Findings The proposed model achieved high sensitivity and specificity in diagnosing lesions on post-therapy radioiodine whole-body scans, outperforming nuclear medicine physicians. Clinical relevance The proposed model was a promising automated diagnostic tool that could assist clinicians in accurately diagnosing lesions on post-therapy radioiodine whole-body scans, potentially reducing patients' need for costly SPECT/CT imaging.
引用
- Chen, Yu, Zhao, et al. DSDFF-YOLO: an automated computer-aided diagnostic method for post-therapy radioiodine whole-body scan. Eur Radiol. 2026. PMID: 42814122. doi:10.1007/s00330-026-12870-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。